Cost-consequence analysis of 18 F-fluciclovine for the staging of recurrent prostate cancer

• Published in: Journal of market access & health policy Vol. 8; no. 1; p. 1749362
• Main Authors: Jensen, Ivar S, Hathway, Joanne, Cyr, Philip, Gauden, David, Gardiner, Peter
• Format: Journal Article
• Language: English
• Published: United States 2020
• Subjects: recurrence; prostate cancer; cost-consequence; budget impact; diagnostic imaging; 18F-fluciclovine
• ISSN: 2001-6689; 2001-6689
• DOI: 10.1080/20016689.2020.1749362

: Current detection methodologies are often unable to identify the location and extent of recurrent prostate cancer (PCa) leading potentially to 'futile' local therapies in the presence of metastatic disease. The use of
 F-fluciclovine PET/CT may lead to better patient management.
: The aim of this study was to quantify the economic impact and cost-consequence of using
 F-fluciclovine PET/CT in PCa recurrence.
: A decision analytic model based on recurrent PCa imaging guidelines.
: US hospital.
: PCa patients experiencing biochemical recurrence.
:
 F-fluciclovine PET/CT was compared to conventional imaging.
: Budget impact, correct diagnoses, futile treatments, and cost-consequence (cost per correct diagnosis)
: For a hypothetical hospital serving 500,000 individuals, the model showed the use of
 F-fluciclovine reduced 'futile' therapies by 19.2%. Re-imaging costs were reduced by 40.2% ($8.2 million); however, when assuming diagnostic and staging costs only, the total costs increased from $31.2 to $34.6 million (10.9%), driven by
 F-fluciclovine imaging agent and procedure costs. The cost per 'correct' diagnosis declined $30,673 (46.8%). When including subsequent 5-year patient management, the cost per 'correct' diagnosis declined $410,206 (49.2%).
:
 F-fluciclovine PET/CT imaging may improve the clinical management of men with recurrent PCa with minimal increase in healthcare spending.